https://www.zonebourse.com/cours/action/SHANGHAI-HENLIUS-BIOTECH--103501663/actualite/Shanghai-Henlius-Biotech-Inc-annonce-le-dosage-du-premier-sujet-d-une-etude-clinique-de-phase-1-s-45560568/?utm_source=telegram&utm_medium=social&utm_campaign=share